STEPHEN KONRAD DE BLOIS
Pilots at 115 St, Seattle, WA
License number
Washington A2715514
Issued Date
Sep 2015
Expiration Date
Sep 2017
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
909 NE 115Th St, Seattle, WA 98125
Professional information
N-Acetylcysteine Compositions And Methods For The Treatment And Prevention Of Drug Toxicity
US Patent:
7723389, May 25, 2010
Filed:
Nov 4, 2002
Appl. No.:
10/287175
Inventors:
Leonard A. Herzenberg - Stanford CA, US
Leonore A. Herzenberg - Stanford CA, US
Stephen C. De Rosa - Seattle WA, US
James Andrus - Redwood City CA, US
Leonore A. Herzenberg - Stanford CA, US
Stephen C. De Rosa - Seattle WA, US
James Andrus - Redwood City CA, US
Assignee:
The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:
A61K 31/195, A61K 31/65, A61K 31/63, A61K 31/60, A61K 31/43, A61K 31/545
US Classification:
514562, 514563, 514561, 514151, 514153, 514154, 514155, 514156, 514157, 514158, 514159, 514192, 514193, 514194, 514195, 514196, 514197, 514198, 514199, 514200, 514201, 514202, 514203, 514204, 514205, 514206, 514207, 514208, 514209
Abstract:
The invention provides pharmaceutical compositions for the treatment or prevention of the toxic effects of therapeutic agents and methods of treating or preventing such toxicity using a toxicity reducing amount of N-acetylcysteine either alone or in combination with a therapeutically effective amount or, to achieve its therapeutic advantages, an amount larger than what is customarily given as a therapeutically effective amount, of a therapeutic agent. The invention also provides pharmaceutical compositions for the treatment or prevention of the toxic effects of therapeutic agents and methods of treating or preventing such toxicity using a toxicity reducing amount of N-acetylcysteine either alone or in combination with a therapeutically effective amount or, to achieve its therapeutic advantages, an amount larger than what is customarily given as a therapeutically effective amount, of a therapeutic agent whose side effects are made worse by increased oxidative stress or treatment related decreases in subject cysteine/glutathione levels or are otherwise relieved by administration of NAC.